<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972022000200004</article-id>
<article-id pub-id-type="doi">10.26445/07.02.4</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de empagliflozina en pacientes diabéticos tipo 2 con insuficiencia cardíaca]]></article-title>
<article-title xml:lang="en"><![CDATA[Use of empagliflozin in type 2 diabetic patients with heart failure]]></article-title>
<article-title xml:lang="pt"><![CDATA[Uso de empagliflozina em pacientes diabéticos tipo 2 com insuficiência cardíaca]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Rojas]]></surname>
<given-names><![CDATA[Zulay Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cristancho Sierra]]></surname>
<given-names><![CDATA[Diana Marcela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peréz Papadópulos]]></surname>
<given-names><![CDATA[Amalia Verónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ormaechea Gorricho]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Clínica Médica A. Unidad Multidisciplinaria de Insuficiencia Cardíaca]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>7</volume>
<numero>2</numero>
<fpage>37</fpage>
<lpage>45</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972022000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972022000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972022000200004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La insuficiencia cardíaca es una patología con alta prevalencia y morbimortalidad. Entre las estrategias terapéuticas se debe considerar el abordaje de las comorbilidades, entre ellas la diabetes mellitus tipo 2. Los pacientes con insuficiencia cardíaca que la asocian, tienen 75% más riesgo de hospitalización y mortalidad. La Food and Drug Administration ha enfatizado desde 2008 que todo nuevo hipoglucemiante debe tener un efecto beneficioso o al menos neutro a nivel cardiovascular. Varios estudios han demostrado que los inhibidores del cotransportador sodio glucosa tipo 2 (empagliflozina, canagliflozina y dapagliflozina) cumplen con estos requerimientos. El objetivo de este trabajo es describir la experiencia en &#8220;vida real&#8221; de la empagliflozina en pacientes con diabetes mellitus 2 e insuficiencia cardíaca con fracción de eyección reducida.  Metodología:  Se realizó un estudio prospectivo, longitudinal, entre julio 2019 - abril 2021 en una Unidad Multidisciplinaria de Insuficiencia Cardíaca.  Resultados:  Se incluyeron 25 pacientes Se incluyeron 25 pacientes (13 hombres) con edad media 61 años. La dosis objetivo de empagliflozina se alcanzó en el 95% de los pacientes. Se observó un descenso de peso, hemoglobina glicosilada y glicemia de ayunas.  Conclusiones:  La empagliflozina presentó buena tolerabilidad, con efectos beneficiosos a nivel cardiovascular y mínimos efectos adversos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Heart failure is a pathology with high prevalence and morbidity and mortality. Among the therapeutic strategies, addressing comorbidities should be considered, including type 2 diabetes mellitus. Patients with associated heart failure have a 75% higher risk of hospitalization and mortality. The Food and Drug Administration has emphasized since 2008 that all new hypoglycemic agents must have a beneficial or at least neutral effect at the cardiovascular level. Several studies have shown that sodium-glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) meet these requirements. The objective of this work is to describe the "real life" experience of empagliflozin in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction.  Methodology:  A prospective, longitudinal study was carried out between July 2019 and April 2021 in a Multidisciplinary Heart Failure Unit.  Results:  Twenty-five patients (13 men) with a mean age of 61 years were included. The target dose of empagliflozin was achieved in 95% of patients. A decrease in weight, glycosylated hemoglobin and fasting blood glucose was observed.  Conclusions:  Empagliflozin presented good tolerability, with beneficial effects at the cardiovascular level and minimal adverse effects.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  A insuficiência cardíaca é uma patologia com alta prevalência e morbidade e mortalidade. Dentre as estratégias terapêuticas, deve-se considerar a abordagem de comorbidades, incluindo diabetes mellitus tipo 2. Pacientes com insuficiência cardíaca associada apresentam risco 75% maior de hospitalização e mortalidade. A Food and Drug Administration tem enfatizado desde 2008 que todos os novos agentes hipoglicemiantes devem ter um efeito benéfico ou pelo menos neutro no nível cardiovascular. Vários estudos mostraram que os inibidores do cotransportador 2 de sódio-glicose (empagliflozina, canagliflozina e dapagliflozina) atendem a esses requisitos. O objetivo deste trabalho é descrever a experiência da "vida real" da empagliflozina em pacientes com diabetes mellitus tipo 2 e insuficiência cardíaca com fração de ejeção reduzida.  Metodologia:  Foi realizado um estudo prospectivo, longitudinal, entre julho de 2019 e abril de 2021 em uma Unidade Multidisciplinar de Insuficiência Cardíaca.  Resultados:  Vinte e cinco pacientes (13 homens) com idade média de 61 anos foram incluídos. A dose alvo de empagliflozina foi alcançada em 95% dos pacientes. Observou-se diminuição do peso, da hemoglobina glicosilada e da glicemia de jejum.  Conclusões:  A empagliflozina apresentou boa tolerabilidade, com efeitos benéficos a nível cardiovascular e efeitos adversos mínimos.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[diabetes mellitus 2]]></kwd>
<kwd lng="es"><![CDATA[insuficiencia cardíaca]]></kwd>
<kwd lng="es"><![CDATA[inhibidores del cotransportador sodio-glucosa tipo 2]]></kwd>
<kwd lng="en"><![CDATA[type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[heart failure]]></kwd>
<kwd lng="en"><![CDATA[sodium-glucose cotransporter type 2 inhibitors]]></kwd>
<kwd lng="pt"><![CDATA[diabetes mellitus tipo 2]]></kwd>
<kwd lng="pt"><![CDATA[insuficiência cardíaca]]></kwd>
<kwd lng="pt"><![CDATA[inibidores do cotransportador sódio-glicose tipo 2]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Cristancho]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ormaechea]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidiabéticos en Insuficiencia Cardíaca]]></article-title>
<source><![CDATA[Rev urug med Interna]]></source>
<year>2021</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>4-21</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunlay]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Givertz]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>140</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e294-324</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saldarriaga-Giraldo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Navas]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From diabetes to heart failure: Does diabetic cardiomyopathy exist?]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Robledo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jaramillo Jaramillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Comín-Colet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus, insuficiencia cardiaca y enfermedad renal crónica]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2020</year>
<volume>27</volume>
<numero>S2</numero>
<issue>S2</issue>
<page-range>3-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-González]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[De la insuficiencia cardiaca a la diabetes ¿Existe un mecanismo común?]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2020</year>
<volume>27</volume>
<numero>S2</numero>
<issue>S2</issue>
<page-range>7-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>FDA</collab>
<source><![CDATA[Announces New Recommendations On Evaluating Cardiovascular Risk In Drugs Intended To Treat Type 2 Diabetes]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Scirica]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Johansen]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>139</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1384-95</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rådholm]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Figtree]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[de Zeeuw]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus Results From the CANVAS Program]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>138</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>458-68</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Mosenzon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Cahn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>347-57</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cavender]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[AZ]]></given-names>
</name>
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Khunti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Holl]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>249-59</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CSP]]></given-names>
</name>
<name>
<surname><![CDATA[Kohsaka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Karasik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lowering Drugs The CVD-REAL 2 Study]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2628-39</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zelniker]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Im]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Goodrich]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes a systematic review and meta-analysis of cardiovascular outcome trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2019</year>
<volume>393</volume>
<numero>10166</numero>
<issue>10166</issue>
<page-range>31-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2021</year>
<volume>143</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>326-36</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cristancho]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ormaechea]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Telemedicina en pandemia: subanálisis del proyecto empaglifozina en diabéticos tipo 2(dm2) con insuficiencia cardíaca con fracción de eyección reducida (ICFER) en la unidad multidisciplinaria en insuficiencia cardiaca (UMIC)]]></source>
<year>2020</year>
<conf-name><![CDATA[ Semana Académica del Hospital de Clínicas]]></conf-name>
<conf-date>2020</conf-date>
<conf-loc>Montevideo </conf-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
